Free Trial

The Cigna Group (CI) Competitors

$332.80
-0.12 (-0.04%)
(As of 01:21 PM ET)

CI vs. ELV, HUM, CNC, GSK, BMY, HCA, GILD, REGN, BSX, and ZTS

Should you be buying The Cigna Group stock or one of its competitors? The main competitors of The Cigna Group include Elevance Health (ELV), Humana (HUM), Centene (CNC), GSK (GSK), Bristol-Myers Squibb (BMY), HCA Healthcare (HCA), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Boston Scientific (BSX), and Zoetis (ZTS). These companies are all part of the "medical" sector.

The Cigna Group vs.

The Cigna Group (NYSE:CI) and Elevance Health (NYSE:ELV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends, earnings and community ranking.

The Cigna Group pays an annual dividend of $5.60 per share and has a dividend yield of 1.7%. Elevance Health pays an annual dividend of $6.52 per share and has a dividend yield of 1.3%. The Cigna Group pays out 46.0% of its earnings in the form of a dividend. Elevance Health pays out 24.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Elevance Health has a net margin of 3.64% compared to The Cigna Group's net margin of 1.76%. Elevance Health's return on equity of 20.62% beat The Cigna Group's return on equity.

Company Net Margins Return on Equity Return on Assets
The Cigna Group1.76% 17.24% 5.09%
Elevance Health 3.64%20.62%7.35%

87.0% of The Cigna Group shares are owned by institutional investors. Comparatively, 89.2% of Elevance Health shares are owned by institutional investors. 0.7% of The Cigna Group shares are owned by insiders. Comparatively, 0.3% of Elevance Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

The Cigna Group received 95 more outperform votes than Elevance Health when rated by MarketBeat users. Likewise, 71.86% of users gave The Cigna Group an outperform vote while only 66.67% of users gave Elevance Health an outperform vote.

CompanyUnderperformOutperform
The Cigna GroupOutperform Votes
927
71.86%
Underperform Votes
363
28.14%
Elevance HealthOutperform Votes
832
66.67%
Underperform Votes
416
33.33%

Elevance Health has lower revenue, but higher earnings than The Cigna Group. Elevance Health is trading at a lower price-to-earnings ratio than The Cigna Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The Cigna Group$195.27B0.48$5.16B$12.1827.33
Elevance Health$171.34B0.69$5.99B$26.4619.11

In the previous week, The Cigna Group had 6 more articles in the media than Elevance Health. MarketBeat recorded 18 mentions for The Cigna Group and 12 mentions for Elevance Health. Elevance Health's average media sentiment score of 1.05 beat The Cigna Group's score of 0.85 indicating that Elevance Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
The Cigna Group
10 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Elevance Health
7 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

The Cigna Group presently has a consensus target price of $366.14, suggesting a potential upside of 9.98%. Elevance Health has a consensus target price of $587.42, suggesting a potential upside of 16.20%. Given Elevance Health's higher possible upside, analysts plainly believe Elevance Health is more favorable than The Cigna Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
The Cigna Group
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.92
Elevance Health
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92

The Cigna Group has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Elevance Health has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Summary

Elevance Health beats The Cigna Group on 12 of the 20 factors compared between the two stocks.

Get The Cigna Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CI vs. The Competition

MetricThe Cigna GroupHospital & medical service plans IndustryMedical SectorNYSE Exchange
Market Cap$94.57B$69.44B$5.13B$17.46B
Dividend Yield1.68%1.36%2.83%3.53%
P/E Ratio27.3321.41171.0125.51
Price / Sales0.480.592,441.8110.12
Price / Cash9.2811.8735.2719.29
Price / Book2.293.865.515.82
Net Income$5.16B$3.43B$105.72M$975.72M
7 Day Performance-1.45%-2.78%0.64%-0.51%
1 Month Performance-6.77%11.80%2.55%2.67%
1 Year Performance37.12%25.65%5.39%22.10%

The Cigna Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELV
Elevance Health
4.7179 of 5 stars
$546.01
+0.8%
$587.42
+7.6%
+13.4%$126.90B$171.34B20.64104,900Analyst Upgrade
Short Interest ↓
HUM
Humana
4.8634 of 5 stars
$355.59
+0.1%
$426.39
+19.9%
-30.5%$42.85B$106.37B22.1467,600Analyst Forecast
Short Interest ↑
CNC
Centene
4.7943 of 5 stars
$78.42
+1.1%
$85.23
+8.7%
+12.4%$41.85B$154.00B15.5967,700Analyst Forecast
Short Interest ↑
News Coverage
Gap Down
GSK
GSK
2.1287 of 5 stars
$44.46
-0.3%
N/A+29.4%$92.14B$37.71B16.1170,200Analyst Forecast
Short Interest ↑
BMY
Bristol-Myers Squibb
4.9446 of 5 stars
$42.29
-2.5%
$60.00
+41.9%
-36.9%$85.73B$45.01B-13.6434,100Analyst Revision
HCA
HCA Healthcare
4.6007 of 5 stars
$321.12
-1.2%
$317.00
-1.3%
+22.9%$84.10B$64.97B16.01310,000Analyst Forecast
Short Interest ↑
GILD
Gilead Sciences
4.9429 of 5 stars
$67.29
-0.9%
$83.69
+24.4%
-17.6%$83.83B$27.12B186.9218,000Positive News
REGN
Regeneron Pharmaceuticals
3.7058 of 5 stars
$993.95
+0.7%
$989.36
-0.5%
+33.3%$109.52B$13.12B29.3613,450Insider Selling
BSX
Boston Scientific
4.5843 of 5 stars
$75.69
+0.4%
$75.32
-0.5%
+46.8%$111.04B$14.24B63.6148,000Analyst Forecast
Insider Selling
Short Interest ↓
News Coverage
ZTS
Zoetis
4.6866 of 5 stars
$172.79
-0.9%
$211.75
+22.5%
+3.7%$78.84B$8.54B33.2914,100Short Interest ↑
Analyst Revision

Related Companies and Tools

This page (NYSE:CI) was last updated on 5/30/2024 by MarketBeat.com Staff

From Our Partners